DK1144005T3 - Behandling af papillomavirusinfektioner - Google Patents

Behandling af papillomavirusinfektioner

Info

Publication number
DK1144005T3
DK1144005T3 DK99966765T DK99966765T DK1144005T3 DK 1144005 T3 DK1144005 T3 DK 1144005T3 DK 99966765 T DK99966765 T DK 99966765T DK 99966765 T DK99966765 T DK 99966765T DK 1144005 T3 DK1144005 T3 DK 1144005T3
Authority
DK
Denmark
Prior art keywords
treatment
infection
vlps
papillomavirus infections
papillomavirus
Prior art date
Application number
DK99966765T
Other languages
Danish (da)
English (en)
Inventor
Ian Frazer
Jian Zhou
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of DK1144005T3 publication Critical patent/DK1144005T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99966765T 1998-12-11 1999-12-13 Behandling af papillomavirusinfektioner DK1144005T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP7653A AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections
PCT/AU1999/001108 WO2000035478A1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections

Publications (1)

Publication Number Publication Date
DK1144005T3 true DK1144005T3 (da) 2007-03-05

Family

ID=3811858

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99966765T DK1144005T3 (da) 1998-12-11 1999-12-13 Behandling af papillomavirusinfektioner

Country Status (12)

Country Link
US (2) US6867033B1 (ja)
EP (1) EP1144005B1 (ja)
JP (2) JP5274737B2 (ja)
KR (1) KR100617485B1 (ja)
AT (1) ATE344053T1 (ja)
AU (1) AUPP765398A0 (ja)
CA (1) CA2353866C (ja)
DE (1) DE69933891T2 (ja)
DK (1) DK1144005T3 (ja)
NZ (1) NZ512850A (ja)
WO (1) WO2000035478A1 (ja)
ZA (1) ZA997638B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629028B1 (ko) * 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
JP6920694B2 (ja) 2015-12-04 2021-08-18 シアメン ユニバーシティXiamen University ヒトパピローマウイルスタイプ11のl1タンパク質の突然変異
US11389525B2 (en) * 2017-10-27 2022-07-19 Statens Serum Institut Polygene influenza vaccine
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194839T3 (es) 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
EP0793752B1 (en) * 1994-09-06 2003-07-09 Scan-Web I/S A method and a system for manufacturing broad airlaid paper webs containing an absorbing powder
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
WO1998010790A1 (en) * 1996-09-11 1998-03-19 Merck & Co., Inc. Papillomavirus vaccine formulation
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE341339T1 (de) * 1996-12-20 2006-10-15 Merck & Co Inc Zusammensetzungen von rekombinanten papillomavirus vakzinen
PT973546E (pt) * 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano
DE19735118C1 (de) * 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Also Published As

Publication number Publication date
ZA997638B (en) 2000-07-06
US6867033B1 (en) 2005-03-15
WO2000035478A1 (en) 2000-06-22
CA2353866C (en) 2013-11-19
US7172870B2 (en) 2007-02-06
EP1144005A4 (en) 2005-02-09
NZ512850A (en) 2004-01-30
KR100617485B1 (ko) 2006-09-01
AUPP765398A0 (en) 1999-01-14
KR20010103711A (ko) 2001-11-23
EP1144005A1 (en) 2001-10-17
DE69933891T2 (de) 2007-06-21
JP2011037902A (ja) 2011-02-24
CA2353866A1 (en) 2000-06-22
US20050244433A1 (en) 2005-11-03
JP2002532434A (ja) 2002-10-02
JP5274737B2 (ja) 2013-08-28
EP1144005B1 (en) 2006-11-02
DE69933891D1 (de) 2006-12-14
ATE344053T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
AU2002360592A1 (en) Inhibitors of hepatitis c virus
LU91314I2 (fr) "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
EP1246644A4 (en) HUMAN PAPILLOMAVIRUS CELLULAR IMMUNE RESPONSE INDUCED BY USE OF PEPTIDE COMPOSITIONS AND NUCLEIC ACID
ID27787A (id) Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
ATE275406T1 (de) Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
DK1144005T3 (da) Behandling af papillomavirusinfektioner
AU2002365240A1 (en) Method and system for early detection of infectious diseases or symptoms of bioterrorism attacks
EA200401528A1 (ru) Производные диарилсульфидов, способ их получения и промежуточные соединения
ATE521361T1 (de) Verfahren zur behandlung von gebärmutterhalskrebs
EP1670507A4 (en) VACCINE FOR THE TREATMENT AND PREVENTION OF HERPES SIMPLEX VIRUS INFECTION
ATE402257T1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
AU4602897A (en) Method for treatment of immunodeficiency virus infection
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
NO20041855L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter
EP0948967A3 (en) Treatment of viral disease in swine
AU2001292947A1 (en) Methods for inhibition of viral infection
PT1392672E (pt) Clorometilacao de tiofeno
SU1503804A1 (ru) Способ мирингопластики
PT1341811E (pt) Preparação de lectinas do visco ingerível por via oral e método
AU2124100A (en) Novel process for the removal of a silyloxy protecting group from 4-silyloxy-tetrahydro-pyran-2-ones
WO2002078717A3 (en) Compositions and methods for reducing rna virus pathogenicity
AU2002247179A1 (en) Treatment of hpv caused diseases
HK1070662A (en) Treatment of micro-organism infection